The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder – A systematic review

Deb, Shoumitro; Farmah, Baldeep; Arshad, Ebrahim; Deb, Tanya; Roy, Meera; Unwin, Gemma

doi:10.1016/j.ridd.2013.12.004

Cited by 56 publications

(29 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aggression, restlessness, autism spectrum disorders, ‘other reasons’ (among these, lack of appropriate environmental circumstances) and previously unsuccessful discontinuation trajectories were all frequently mentioned reasons. In previous studies, it was shown that symptoms of autism may benefit from treatment with antipsychotics, although the quality of the studies was generally poor (Tsiouris et al , Deb et al , Wink et al , Park et al ). Thus, autism as reason not to discontinue may be a valid reason in some cases.…”

Section: Discussionmentioning

confidence: 99%

Physicians' reasons not to discontinue long‐term used off‐label antipsychotic drugs in people with intellectual disability

Kuijper

Hoekstra

2017

J intellect Disabil Res

View full text Add to dashboard Cite

The prevalence of antipsychotic drug use for off-label indications in people with ID remains high. The results of this study indicate that there is a large variation in clinical practice of physicians regarding discontinuation of long-term antipsychotic drug prescriptions, which may be partially related to environmental factors as setting culture and attitudes of staff towards off-label antipsychotic drug use in persons with ID.

show abstract

Section: Discussionmentioning

confidence: 99%

Physicians' reasons not to discontinue long‐term used off‐label antipsychotic drugs in people with intellectual disability

Kuijper

Hoekstra

2017

J intellect Disabil Res

View full text Add to dashboard Cite

show abstract

“…As a treatment for ASD, such medications should be combined with patient/family education and/or psychosocial intervention [3]; however, the mutism has often failed to show improvement with SSRI treatment, and particularly in Japan, the psychosocial interventions for patients with ASD cannot be conducted due to healthcare facilities limitations. In previous studies [3][4][5][6][7], alterations of neurotransmitters have been demonstrated in ASD patients including lower gamma-aminobutyric acid (GABA) levels, higher glutamate levels, hyperserotonemia, and increased dopamine turnover. In particular, social disabilities in ASD patients were revealed to be related to abnormalities in both the glutamate [3,7,8] and dopamine systems [4][5][6][7].…”

Section: Discussionmentioning

confidence: 99%

Mutism in an adult case with autism spectrum disorder improved by aripiprazole

Sato

Watanabe²,

Ide

et al. 2019

CNPT

View full text Add to dashboard Cite

Autism spectrum disorder (ASD) includes disturbances in communication, imagination, and social interaction. In individuals with ASD, selective mutism is a common symptom of a communication disability. Selective serotonin reuptake inhibitors (SSRIs) have been recommended to treat selective mutism, especially after psychosocial interventions fail. However, the mechanism and efficacy of SSRIs in treating selective mutism remain unclear. Here we report the case of an adult male with ASD whose selective mutism was improved by aripiprazole but not SSRIs. To the best of our knowledge, this is the first such case report. We believe that our patient's case highlights the value of differentiating between psychopathology and psychopharmacology when examining ASD symptoms.

show abstract

“…It has been usually regarded as a dopamine system stabilizer as, in high levels of dopamine production, it will act as an antagonist and where dopamine activity is low, it will act as an agonist (Deb et al 2014). In the literature, both dopaminergic and antidopaminergic agents have been reported to be related with the development of hiccups (Miyaoka and Kamijima 1999;Gerschlager and Bloem 2009).…”

Section: Discussionmentioning

confidence: 99%